Aura Biosciences Inc (AURA)vsRevolution Medicines Inc (RVMD)
AURA
Aura Biosciences Inc
$6.63
-2.50%
HEALTHCARE · Cap: $713.37M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
AURA
Avoid22
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AURA
The strongest argument for AURA centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : AURA
The primary concerns for AURA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
AURA is growing revenue faster at 0.0% — sustainability is the question.
AURA generates stronger free cash flow (-30M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 22/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aura Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its proprietary virus-like particle (VLP) technology. Its lead investigational drug, AU-011, is designed to selectively target and eradicate ocular cancer cells, minimizing damage to surrounding healthy tissue, which underscores significant advancements in precision oncology. With a robust clinical pipeline addressing critical unmet needs in cancer therapy and backed by an experienced management team, Aura is strategically positioned to make notable strides in the oncology market. The company’s collaborative partnerships further bolster its innovation potential, aligning with the increasing demand for targeted therapies in the modern healthcare ecosystem.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?